RxDoctor Payments Data

Kristin Gildersleeve, MD

Family Medicine · Hebron, CTNPI 1902846082

Payments from drug & device makers

$1,721in general payments, 2019–2025

Across 47 payments — averaging $36.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$301
  • Axsome Therapeutics, Inc.$265
  • AbbVie$223
  • Novo Nordisk$219
  • Lilly USA, LLC$195
  • Pfizer$179
  • plus $341 from 6 others

What the payments were for

  • Food & beverage$1,70499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,721 in reported general payments places this provider in the 75th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$58,992
Medicare patients
186
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$92,042
MounjaroTirzepatide55$66,891
EliquisApixaban63$63,779
JardianceEmpagliflozin44$48,563
LinzessLinaclotide77$40,911
XareltoRivaroxaban20$32,402
ProliaDenosumab12$21,106
JanuviaSitagliptin Phosphate17$16,653
Janumet XrSitagliptin Phos/Metformin Hcl16$13,419
LokelmaSodium Zirconium Cyclosilicate12$10,467
MyrbetriqMirabegron14$8,762
RestasisCyclosporine11$7,453
Pantoprazole Sodium158$6,854
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate11$6,757
Atorvastatin Calcium647$5,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$219$92,04278 claims
PfizerEliquis, Premarin$179$68,95874 claims
Lilly USA, LLCMounjaro$195$66,89155 claims
AbbVieLinzess, Restasis, Synthroid$223$51,460120 claims
AmgenProlia$301$21,10612 claims
AstraZenecaLokelma$145$10,46712 claims
Almatica Pharma LLCSertraline Hcl$26$1,626151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Hebron

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →